Changes of TSH-Stimulation Blocking Antibody (TSBAb)‎ and Thyroid Stimulating Antibody (TSAb)‎ Over 10 Years in 34 TSBAb-Positive Patients with Hypothyroidism and in 98 TSAb-Positive Graves’ Patients with Hyperthyroidism : Reevaluation of TSBAb and TSAb in TSH-Receptor-Antibody (TRAb)‎-Positive Patients

Abstract EN

Two TRAbs: TSBAb and TSAb.

TSBAb causes hypothyroidism.

TSAb causes Graves’ hyperthyroidism.

TSBAb and TSAb block TSH-binding to cells as TRAb, measured as TSH-binding inhibitory immunoglobulin (TBII).

We reevaluate TSBAb and TSAb.

We studied TSBAb, TSAb, and TBII over 10 years in 34 TSBAb-positives with hypothyroidism and in 98 TSAb-positives with hyperthyroidism.

Half of the 34 TSBAb-positives with hypothyroidism continued to have persistently positive TSBAb, continued to have hypothyroidism, and did not recover from hypothyroidism.

Ten of the 98 TSAb-positives with hyperthyroidism continued to have positive TSAb and continued to have hyperthyroidism.

TSBAb had disappeared in 15 of the 34 TSBAb-positives with hypothyroidism.

With the disappearance of TSBAb, recovery from hypothyroidism was noted in 13 (87%) of the 15 patients.

TSAb had disappeared in 73 of the 98 TSAb-positives with hyperthyroidism.

With the disappearance of TSAb, remissions of hyperthyroidism were noted in 60 (82%) of the 73.

Two of the 34 TSBAb-positives with hypothyroidism developed TSAb-positive Graves’ hyperthyroidism.

Two of the 98 TSAb-positive Graves’ patients with hyperthyroidism developed TSBAb-positive hypothyroidism.

TSBAb and TSAb are TRAbs.

TSBAb-hypothyroidism and TSAb-hyperthyroidism may be two aspects of one disease (TRAb disease).

Two forms of autoimmune thyroiditis: atrophic and goitrous.

We followed 34 TSBAb-positive patients with hypothyroidism (24 atrophic and 10 goitrous) over 10 years.

All of the 10 TSBAb-positive goitrous patients recovered from hypothyroidism and 19 (79%) of the 24 TSBAb-positive atrophic patients continued to have hypothyroidism.